Long Shortz with Optiscan: New partnership targets real-time cancer detection

Optiscan has partnered with Long Grove Pharmaceuticals to see Long Grove’s AK-FOUR used in combination with OIL’s tech.

Tylah Tully chats with Optiscan Imaging (ASX:OIL) CEO Camille Farah about the company’s new agreement with Long Grove Pharmaceuticals, pairing Long Grove's fluorescein drug, AK-FLUOR, in combination with OIL's imaging technology in clinical studies and trials. 

The partnership supports upcoming FDA submissions for both Optiscan's InVue surgical device and Long Grove’s drug candidate, initially targeting breast cancer surgery and expanding into broader clinical applications.

Watch the video to learn more.

This video was developed in collaboration with Optiscan Imaging, a Stockhead client at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.

Originally published as Long Shortz with Optiscan: New partnership targets real-time cancer detection